Prosecution Insights
Last updated: April 19, 2026
Application No. 18/304,567

POLYHYDROXY MULTI-IONIC COMPOUNDS AND METHODS OF MAKING AND USE THEREOF

Non-Final OA §112
Filed
Apr 21, 2023
Examiner
SAWYER, JENNIFER C
Art Unit
1691
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Ecolab Usa Inc.
OA Round
1 (Non-Final)
69%
Grant Probability
Favorable
1-2
OA Rounds
2y 9m
To Grant
58%
With Interview

Examiner Intelligence

Grants 69% — above average
69%
Career Allow Rate
375 granted / 545 resolved
+8.8% vs TC avg
Minimal -11% lift
Without
With
+-10.6%
Interview Lift
resolved cases with interview
Typical timeline
2y 9m
Avg Prosecution
45 currently pending
Career history
590
Total Applications
across all art units

Statute-Specific Performance

§101
0.2%
-39.8% vs TC avg
§103
43.9%
+3.9% vs TC avg
§102
19.4%
-20.6% vs TC avg
§112
24.7%
-15.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 545 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Detailed Action This office action is in response to applicant’s communication filed on 1/8/26. Claims 1, 16-22, 25 and 101-111 are pending. Applicant’s election without traverse of Group I, claim 1 in the reply filed on 12/10/2025 is acknowledged. Thus Claims 16-22 and 25 are withdrawn from further consideration being drawn to the nonelected invention. As a result, claims 1 and 101-111 are being examined in this Office Action. Priority The applicant claims benefit as follows: PNG media_image1.png 58 388 media_image1.png Greyscale Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. Claims 1 and 101-111 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor regards as the invention. Claims 1, 106 and 109-110 includes -PO3H for the definition for Z. The examiner believes either a negative charge should be included or another hydrogen is missing. Does the applicant mean phosphonate, -PO3H2, instead? Claim 1 recites the following structure of formula (VII) PNG media_image2.png 372 374 media_image2.png Greyscale The claim is rejected because the structure of formula (VII) is blurry and difficult to discern. In particular, the examiner can not discern the atoms that cap the two parenthetical amines at the right and left of the structure of formula (VII), which are circled below. Furthermore, since there appears to be an open substitution outside the two parenthetical amines, circled below, this would constitute an incomplete partial structure. Partial structures are considered indefinite, since the structure of the entire compound is unclear. The examiner recommends the applicant include a clear structure of formula (VII), in which the atoms that cap the right and left parenthetical amines are inserted clearly, so that there are no open sites in the structure of formula (VII). PNG media_image3.png 386 392 media_image3.png Greyscale The dependent claims are rejected as being dependent on a rejected claim. Objections Claims 1, 101-102 and 107-111 are objected to because of the recitation of “formula V” and/or or “formula VII”. The examiner recommends the applicant include parenthesis around (V) and (VII) to match the labels below the structures in claim 1. The disclosure is objected to because of the following informalities: Similar to the 112 rejection above, the structures of formula (VII) and (VI), throughout applicant’s specification, are blurry and contain an incomplete partial structure, since it is unclear what caps the right and left parenthetical amines. For example, in applicant’s PGPUB (US 20230339849) on page 2, the structure of formula (VII) is so blurry, question marks are included as shown below: PNG media_image4.png 402 478 media_image4.png Greyscale Appropriate correction is required. Objections The drawings are objected to for similar reasons to the objection to applicant’s specification, shown above. Applicant’s structure of formula (VII) and (VI) in Figure 2 are blurry and contain an incomplete partial structure, since it is unclear what caps the right and left parenthetical amines. See structures below: PNG media_image5.png 490 458 media_image5.png Greyscale PNG media_image6.png 248 314 media_image6.png Greyscale Corrected drawing sheets in compliance with 37 CFR 1.121(d) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. The figure or figure number of an amended drawing should not be labeled as “amended.” If a drawing figure is to be canceled, the appropriate figure must be removed from the replacement sheet, and where necessary, the remaining figures must be renumbered and appropriate changes made to the brief description of the several views of the drawings for consistency. Additional replacement sheets may be necessary to show the renumbering of the remaining figures. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either “Replacement Sheet” or “New Sheet” pursuant to 37 CFR 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance. Art of Interest Song et al. (Biomacromolecules, 2020, 21(12), 5345-5357) teaches the following polyhydroxy compound (see Figure 1, page 5348), which shows the structure of the polyhydroxy compound and the 1HNMR: PNG media_image7.png 844 954 media_image7.png Greyscale Song et al. is deficient because it does not teach applicant’s carbon backbone or applicant’s Z group. Conclusion Claims 1 and 101-111 are rejected. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jennifer Cho Sawyer whose telephone number is (571) 270 1690. The examiner can normally be reached on Monday-Friday 9 AM - 6 PM PST. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Renee Claytor can be reached on (571) 272-8394. The fax phone number for the organization where this application or proceeding is assigned is 571-274-1690. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. Jennifer Cho Sawyer Patent Examiner Art Unit: 1691 /RENEE CLAYTOR/Supervisory Patent Examiner, Art Unit 1691
Read full office action

Prosecution Timeline

Apr 21, 2023
Application Filed
Feb 07, 2026
Non-Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12552735
PROCESS FOR THE SYNTHESIS OF TWIN-TAIL TRIAMINES
2y 5m to grant Granted Feb 17, 2026
Patent 12552753
Methods and Compositions for Targeting Tregs using CCR8 Inhibitors
2y 5m to grant Granted Feb 17, 2026
Patent 12528758
PRODUCTION OF AROMATIC ACIDS AND PHENOLICS
2y 5m to grant Granted Jan 20, 2026
Patent 12528765
CONTINUOUS SYNTHESIS METHOD OF 2-ACETAMIDO-5-NITROANISOLE
2y 5m to grant Granted Jan 20, 2026
Patent 12509417
ENANTIOSELECTIVE PROCESS
2y 5m to grant Granted Dec 30, 2025
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
69%
Grant Probability
58%
With Interview (-10.6%)
2y 9m
Median Time to Grant
Low
PTA Risk
Based on 545 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month